Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

Angeles, California; founder and director-emeritus of The New England Center for Headache; and clinical investigator for the Phase II study.

Merck continues to anticipate filing a New Drug Application (NDA) for MK-0974 with the U.S. Food and Drug Administration in 2009.

About migraines

Migraine headaches impact approximately 28 million Americans, primarily women. Unlike a bad headache, migraines are characterized by attacks of intense, usually one-sided, throbbing head pain that can last from four to 72 hours. The pain associated with migraine is frequently accompanied by other associated symptoms, including nausea, vomiting and increased sensitivity to light and/or sound.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:5/22/2015)... DUBLIN , May 20, 2015 ... addition of the "Guide to Prepare Application ... in China (2014 Edition) " report to ... market is one of segment market of the ... more overseas medical device manufacturers and producers to ...
(Date:5/22/2015)... 22, 2015 Research and Markets ... the "Latest Regulations on Pharmaceutical International Multi-Center ... offering. This is first time in ... on international multi-center clinical trials of drugs in ... to be implemented on March 1, 2015. The ...
(Date:5/22/2015)... May 22, 2015  In a sweeping analysis assessing ... T1D Exchange researchers conclude that there remains ... diabetes across all age groups, but especially for adolescents ... picture of diabetes treatment, underscoring the need to address ... that can help type 1 patients achieve optimal metabolic ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 32015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM ... announced that it will be hosting the autumn eClinical ... in Fort Lauderdale, Florida from November 03-05, 2010. The ... Life Science organizations. The informal ambiance provides support for ...
... Calif., Sept. 21 Bionovo, Inc. (Nasdaq: BNVI, BNVID), a ... in women,s health and oncology, today announced that Dr. Isaac ... at the JMP Securities Healthcare Conference at 4:00 p.m. ET ... at the New York Palace hotel in New York City. ...
Cached Medicine Technology:OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3Bionovo to Present at the JMP Securities Healthcare Conference 2
(Date:5/22/2015)... May 22, 2015 Family, friends, students, ... world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on Monday, ... luncheon began after Grand Rounds in the hospital’s Tower ... anxiously outside the auditorium, trying to keep the secret. ... if he sees me, he’ll know something is up,” ...
(Date:5/22/2015)... 22, 2015 Power Systems is proud to ... 2015 race season. Drobeck is in his second year of ... firefighter with the Missoula Fire Department in Missoula, MT. He ... in 2014. During his career, he has had 15 1st ... recorded top 10 finishes in all seven of his 2014 ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all forms of ... in include decks, additions, kitchen remodeling, interior renovations, exterior ... , The redesigned logo is a fresh modern ... includes two geometrical lines that represent the engineering aspect ... used with many things associated with the company. The ...
(Date:5/22/2015)... May 22, 2015 DMG Productions announces ... scheduled to broadcast on Friday, May 29, 2015 at ... Channel. , In this episode Innovations will explore Interstate ... to business quickly through disaster recovery and restoration. , ... that works collaboratively to develop and deliver training and ...
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS have ... to immediately deliver fully integrated dental implant services to their ... medical surgeon. , The Center, whose name is ... from placing dental implants. These 6 roadblocks can discourage ... surgical placement of dental implants into his or her practice. ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2
... first time to date, research published in the October ... sought to determine the use of chemotherapy in ... encompassing all patient ages. Prior population-based studies have shown ... cancer patients receive chemotherapy treatment. These studies have previously ...
... Researchers from the Arkansas Epilepsy Program found treatment with ... compared with placebo, for patients with uncontrolled partial-onset seizures ... in Epilepsia , a journal published by Wiley-Blackwell ... Epilepsy affects up to 2% of the worldwide ...
... papillomavirus (HPV) DNA-based testing or visual inspection of the ... had a statistically significant reduction in high grade cervical ... according to a study published online Sept. 30 in ... In many developing countries, especially in ...
... of Health scientists could explain how Salmonella bacteria, a ... In a study published this week in the ... describe finding a reservoir of rapidly replicating Salmonella inside ... cells and are pushed from the epithelial layer by ...
... MEDFORD/SOMERVILLE, Mass.--Researchers from Tufts University School of Engineering and ... precursors to the potent anti-cancer compound Taxol in an ... The findings are significant steps on the way to ... to design new Taxol-like pharmaceuticals. The work ...
... Louisville School of Nursing has earned a $792,000 grant ... Health Resources and Services Administration to develop nursing informatics ... well as practicing nurses from University of Louisville Hospital. ... a tsunami of patient data in order to make ...
Cached Medicine News:Health News:New lung cancer research finds half of advanced lung cancer patients receive chemotherapy 2Health News:Adjunctive rufinamide reduces refractory partial-onset seizures 2Health News:HPV screen-and treat-intervention effective in cervical cancer prevention 2Health News:NIH scientists describe how salmonella bacteria spread in humans 2Health News:Researchers advance biosynthesis of potent anti-cancer drug Taxol 2Health News:UofL School of Nursing awarded grant to fund new informatics education project 2
This product is for the upper body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
... system delivers cold air to the patient ... temperatures down to 10C. Cooling the body ... been used as a therapeutic tool, particularly ... hypothermia is now widely used as a ...
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Whole blood tube use for microbiology...
Medicine Products: